Researchers have made significant progress in treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), two serious lung diseases that can severely impact breathing. A new oral medication called JASCAYD® (nerandomilast) has received a positive recommendation for marketing authorization in Europe. This is notable as it is the first new treatment option for IPF in over ten years, offering hope to the more than 500,000 people affected by these conditions in the EU.

For those looking to maintain their lung health as they age, this new treatment could mean a slower decline in lung function. Clinical trials showed that nerandomilast significantly slowed the decline in lung function over a year compared to a placebo. While the drug did not meet all secondary endpoints, it showed a potential reduction in mortality rates, which is critical given that about half of those diagnosed with IPF or PPF may not survive beyond five years. The drug is particularly promising for older adults, who are more likely to develop these conditions.

The evidence comes from the FIBRONEER™ program, which is the largest clinical trial series for IPF and PPF to date. The results are strong but still early-stage, as the drug has yet to be fully approved in Europe. While the findings are encouraging, it’s essential to approach this news with caution, as more data will be needed to confirm the long-term benefits and safety of nerandomilast for patients.

If you or someone you know is dealing with IPF or PPF, it may be worthwhile to discuss this new treatment option with a healthcare provider, especially as it may offer a more tolerable alternative to existing therapies that often come with challenging side effects.

Source: globenewswire.com